Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its topology in neuroblastoma cells

Molecular and Cellular Neuroscience

Volumn 37, Issue 4, 2008, Pages 647-656

  Gu, Yaping ^a   Singh, Ajay ^a   Bose, Sharmila ^a   Singh, Neena ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CtmPrP; Familial prion disorders; GPI signal peptide; Mutant PrP; Post translational ER translocation; PrP transport

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL;

ARTICLE; CELL MEMBRANE; ENDOPLASMIC RETICULUM; GENE TRANSLOCATION; GENETIC TRANSFECTION; LIPID BILAYER; NEUROBLASTOMA CELL; NEUROTOXICITY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN TRANSPORT;

CELL LINE, TUMOR; GLYCOSYLPHOSPHATIDYLINOSITOLS; HUMANS; MUTATION; NEUROBLASTOMA; PRIONS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN SORTING SIGNALS; SIGNAL TRANSDUCTION;

EID: 41149144037     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2007.08.018     Document Type: Article

References (41)

1. Aguzzi A., and Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 116 (2004) 313-327
2. Caras I.W., and Weddell G.N. Signal peptide for protein secretion directing glycophospholipid membrane anchor attachment. Science 243 (1989) 1196-1198
3. Chabry J., Ratsimanohatra C., Sponne I., Elena P.P., Vincent J.P., and Pillot T. In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P118-135 independently of PrP expression. J. Neurosci. 23 (2003) 462-469
4. Chesebro B., Trifilo M., Race R., Meade-White K., Teng C., LaCasse R., Raymond L., Favara C., Baron G., Priola S., Caughey B., Masliah E., and Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308 (2005) 1435-1439
5. Field M.C., Moran P., Li W., Keller G.A., and Caras I.W. Retention and degradation of proteins containing an uncleaved glycosylphosphatidylinositol signal. J. Biol. Chem. 269 (1994) 10830-10837
6. Gu Y., Fujioka H., Mishra R.S., Li R., and Singh N. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J. Biol. Chem. 277 (2002) 2275-2286
7. Gu Y., Verghese S., Mishra R.S., Xu X., Shi Y., and Singh N. Mutant prion protein-mediated aggregation of normal prion protein in the endoplasmic reticulum: implications for prion propagation and neurotoxicity. J. Neurochem. 84 (2003) 10-22
8. Gu Y., Luo X., Basu S., Fujioka H., and Singh N. Cell-specific metabolism and pathogenesis of transmembrane prion protein. Mol. Cell Biol. 26 (2006) 2697-2715
9. Haik S., Peyrin J.M., Lins L., Rosseneu M.Y., Brasseur R., Langeveld J.P., Tagliavini F., Deslys J.P., Lasmezas C., and Dormont D. Neurotoxicity of the putative transmembrane domain of the prion protein. Neurobiol. Dis. 7 (2000) 644-656
10. Harris D.A., and True H.L. New insights into prion structure and toxicity. Neuron. 50 (2006) 353-357
11. Hegde R.S., Mastrianni J.A., Scott M.R., DeFea K.A., Tremblay P., Torchia M., DeArmond S.J., Prusiner S.B., and Lingappa V.R. Transmembrane form of the prion protein in neurodegenerative disease. Science 279 (1998) 827-834
12. Hegde R.S., Voigt S., and Lingappa V.R. Regulation of protein topology by trans-acting factors at the endoplasmic reticulum. Mol. Cell 2 (1998) 85-91
13. Hegde R.S., Tremblay P., Groth D., DeArmond S.J., Prusiner S.B., and Lingappa V.R. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402 (1999) 822-826
14. Heller U., Winklhofer K.F., Heske J., Reintjes A., and Tatzelt J. Post-translational import of the prion protein into the endoplasmic reticulum interferes with cell viability: a critical role for the putative transmembrane domain. J. Biol. Chem. 278 (2003) 36139-36147
15. Hölscher C., Bach U.C., and Dobberstein B. Prion protein contains a second endoplasmic reticulum targeting signal sequence located at its C terminus. J. Biol. Chem. 276 (2001) 13388-13394
16. Hoque M.Z., Kitamoto T., Furukawa H., Muramoto T., and Tateishi J. Mutation in the prion protein gene at codon 232 in Japanese patients with Creutzfeldt-Jakob disease: a clinicopathological, immunohistochemical and transmission study. Acta Neuropathol. (Berl). 92 (1996) 441-446
17. Jin T., Gu Y., Zanusso G., Sy M., Kumar A., Cohen M., Gambetti P., and Singh N. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J. Biol. Chem. 275 (2000) 38699-38704
18. Kiachopoulos S., Bracher A., Winklhofer K.F., and Tatzelt J. Pathogenic mutations located in the hydrophobic core of the prion protein interfere with folding and attachment of the glycosylphosphatidylinositol anchor. J. Biol. Chem. 280 (2005) 9320-9329
19. Kim S.J., and Hegde R.S. Co-translational partitioning of nascent prion protein into multiple populations at the translocation channel. Mol. Biol. Cell 13 (2002) 3775-3786
20. Kitamoto T., Ohta M., Dohura K., Hitoshi S., Terao Y., and Tateishi J. Novel missense variants of prion protein in Creutzfeldt-Jakob disease or Gerstmann-Straussler syndrome. Biochem. Biophys. Res. Commun. 191 (1993) 709-714
21. Lu Y., Xiong X., Helm A., Kimani K., Bragin A., and Skach W.R. Co- and posttranslational translocation mechanisms direct cystic fibrosis transmembrane conductance regulator N terminus transmembrane assembly. J. Biol. Chem. 273 (1998) 568-576
22. Ma J., Wollmann R., and Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science. 298 (2002) 1781-1785
23. Moise A.R., Grant J.R., Lippe R., Gabathuler R., and Jefferies W.A. The adenovirus E3-6.7K protein adopts diverse membrane topologies following posttranslational translocation. J. Virol. 78 (2004) 454-463
24. Moran P., Raab H., Kohr W.J., and Caras I.W. Glycophospholipid membrane anchor attachment. Molecular analysis of the cleavage/attachment site. J. Biol. Chem. 266 (1991) 1250-1257
25. Orsi A., Fioriti L., Chiesa R., and Sitia R. Conditions of endoplasmic reticulum stress favor the accumulation of cytosolic prion protein. J. Biol. Chem. 281 (2006) 30431-30438
26. Ott C.M., and Lingappa V.R. Integral membrane protein biosynthesis: why topology is hard to predict. J. Cell Sci. 115 (2002) 2003-2009
27. Ott C.M., and Lingappa V.R. Signal sequences influence membrane integration of the prion protein. Biochemistry 43 (2004) 11973-11982
28. Ott C.M., Akhavan A., and Lingappa V.R. Specific features of the prion protein transmembrane domain regulate nascent chain orientation. J. Biol. Chem. 282 (2007) 11163-11171
29. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
30. Rambold A.S., Miesbauer M., Rapaport D., Bartke T., Baier M., Winklhofer K.F., and Tatzelt J. Association of Bcl-2 with misfolded prion protein is linked to the toxic potential of cytosolic PrP. Mol. Biol. Cell 17 (2006) 3356-3368
31. Rane N.S., Yonkovich J.L., and Hegde R.S. Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J. 23 (2004) 4550-4559
32. Rogers M., Yehiely F., Scott M., and Prusiner S.B. Conversion of truncated and elongated prion proteins into the scrapie isoform in cultured cells. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3182-3186
33. Roucou X., Guo Q., Zhang Y., Goodyer C.G., and LeBlanc A.C. Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons. J. Biol. Chem. 278 (2003) 40877-40881
34. Schnell D.J., and Hebert D.N. Protein translocons: multifunctional mediators of protein translocation across membranes. Cell 112 (2003) 491-505
35. Singh N., Gu Y., Bose S., Basu S., Luo X., Mishra R., and Kuruvilla O. Processing and mis-processing of the prion protein: insights into the pathogenesis of familial prion disorders. In: David B. (Ed). Neurodegeneration and Prion Disease (2005), Life Sciences, Springer 299-318
36. Stewart R.S., and Harris D.A. Mutational analysis of topological determinants in prion protein (PrP) and measurement of transmembrane and cytosolic PrP during infection. J. Biol. Chem. 278 (2003) 45960-45968
37. Stewart R.S., Piccardo P., Ghetti B., and Harris D.A. Neurodegenerative illness in transgenic mice expressing a transmembrane form of the prion protein. J. Neurosci. 25 (2005) 3469-3477
38. Udenfriend S., and Kodukula K. Prediction of omega site in nascent precursor of glycosylphosphatidylinositol protein. Methods Enzymol. 250 (1995) 571-582
39. Wadsworth J.D., Hill A.F., Beck J.A., and Collinge J. Molecular and clinical classification of human prion disease. Br. Med. Bull. 66 (2003) 241-254
40. Windl O., Giese A., Schulz-Schaeffer W., Zerr I., Skworc K., Arendt S., Oberdieck C., Bodemer M., Poser S., and Kretzschmar H.A. Molecular genetics of human prion diseases in Germany. Hum. Genet. 105 (1999) 244-252
41. Winklhofer K.F., Heller U., Reintjes A., and Tatzelt J. Inhibition of complex glycosylation increases the formation of PrPsc. Traffic 4 (2003) 313-322